(NP (NP (NN Objective)) (: :) (S (S (VP (VBG Mining) (NP (NP (DT the) (NN data)) (VP (VBD contained) (PP (IN within) (NP (NP (NNP Electronic) (NNP Health) (NNP Records)) (PRN (-LRB- -LRB-) (NP (NNP EHRs)) (-RRB- -RRB-)))))))) (VP (MD can) (ADVP (RB potentially)) (VP (VB generate) (NP (NP (DT a) (JJR greater) (NN understanding)) (PP (IN of) (NP (NP (NN medication) (NNS effects)) (PP (IN in) (NP (DT the) (JJ real) (NN world)))))) (, ,) (S (VP (VBG complementing) (SBAR (WHNP (WP what)) (S (NP (PRP we)) (VP (VBP know) (PP (IN from) (NP (NP (VBN Randomised) (NN control) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNP RCTs)) (-RRB- -RRB-)))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP Propose) (NP (NP (DT a) (NN text) (NN mining) (NN approach)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (NP (JJ adverse) (NNS events)) (CC and) (NP (NN medication) (NNS episodes))) (PP (IN from) (NP (DT the) (JJ clinical) (NN text))) (S (VP (TO to) (VP (VB enhance) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (VP (VBN related) (PP (TO to) (NP (NP (NNP Clozapine)) (, ,) (NP (NP (NP (DT the) (ADJP (RBS most) (JJ effective)) (JJ antipsychotic) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ treatment-resistant) (NN schizophrenia)))))) (, ,) (CC but) (VP (VBD underutilised) (PP (JJ due) (TO to) (NP (NP (NNS concerns)) (PP (IN over) (NP (PRP$ its) (NN side) (NNS effects)))))))))))))))))))))) (. .))
(NP (NP (NN Material) (CC and) (NNS Methods)) (: :) (S (NP (PRP We)) (VP (VBD used) (NP (NP (NNS data)) (PP (IN from) (NP (NP (NP (JJ de-identified) (NNP EHRs)) (PP (IN of) (NP (NP (CD three) (JJ mental) (NN health) (NNS trusts)) (PP (IN in) (NP (DT the) (NNP UK)))))) (PRN (-LRB- -LRB-) (NP (NP (QP ($ >) (CD 50) (CD million)) (NNS documents)) (, ,) (NP (QP (IN over) (CD 500,000)) (NNS patients)) (, ,) (SBAR (WHNP (WHNP (CD 2835)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD were) (VP (VBN prescribed) (NP (NNP Clozapine))))))) (-RRB- -RRB-))))))) (. .))
(S (NP (PRP We)) (VP (VBD explored) (NP (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (CD 33) (JJ adverse) (NNS effects)) (PP (IN by) (NP (NP (NN age)) (, ,) (NP (NN gender)) (, ,) (NP (NN ethnicity)) (, ,) (NP (VBG smoking) (NN status)) (CC and) (NP (NN admission) (NN type))))))) (SBAR (UCP (NP (CD three) (NNS months)) (IN before) (CC and) (IN after)) (S (NP (DT the) (NNS patients)) (VP (VBD started) (NP (NNP Clozapine) (NN treatment))))))) (. .))
(S (NP (PRP We)) (VP (VBN compared) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ adverse) (NNS effects)))) (PP (IN with) (NP (NP (DT those)) (VP (VBN reported) (PP (IN in) (NP (NP (DT the) (NNP Side) (NNP Effects) (NNP Resource)) (PRN (-LRB- -LRB-) (NP (NNP SIDER)) (-RRB- -RRB-))))))) (SBAR (WHADVP (WRB where)) (FRAG (ADJP (JJ possible))))) (. .))
(NP (NP (NNS Results)) (: :) (S (NP (NP (NNP Sedation)) (, ,) (NN fatigue) (, ,) (NP (NN agitation)) (, ,) (NP (NN dizziness)) (, ,) (NP (NN hypersalivation)) (, ,) (NP (VBD weight) (NN gain)) (, ,) (NP (NN tachycardia)) (, ,) (NP (NN headache)) (, ,) (NP (NN constipation)) (CC and) (NP (NN confusion))) (VP (VBD were) (PP (PDT amongst) (NP (NP (DT the) (JJS highest) (JJ recorded) (NNP Clozapine) (NN adverse) (NN effect)) (PP (IN in) (NP (NP (DT the) (CD three) (NNS months)) (PP (VBG following) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN treatment))))))))))) (. .))
(S (NP (NP (JJR Higher) (NNS percentages)) (PP (IN of) (NP (DT all) (JJ adverse) (NNS effects)))) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (JJ first) (NN month)) (PP (IN of) (NP (NNP Clozapine) (NN therapy))))))) (. .))
(S (S (VP (VBG Using) (NP (NP (DT a) (NN significance) (NN level)) (PP (IN of) (PRN (-LRB- -LRB-) (NP (JJ p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))) (ADVP (IN out)))) (NP (NN chi-square) (NNS tests)) (VP (VBP show) (NP (NP (DT a) (JJ significant) (NN association)) (PP (IN between) (NP (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (NNP ADRs))) (PP (IN in) (NP (NP (VBG smoking) (NN status)) (CC and) (NP (NN hospital) (NNS admissions))))) (CC and) (NP (NP (DT some)) (PP (IN in) (NP (NN gender) (CC and) (NN age) (NNS groups)))))))) (. .))
(S (ADVP (RB Further)) (, ,) (S (NP (DT the) (NN data)) (VP (VBD was) (VP (VBN combined) (PP (IN from) (NP (CD three) (NNS trusts)))))) (, ,) (CC and) (S (NP (JJ chi-square) (NNS tests)) (VP (VBD were) (VP (VBN applied) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (JJ average) (NN effect)) (PP (IN of) (NP (NNP ADRs))) (PP (IN in) (NP (DT each) (JJ monthly) (NN interval)))))))))) (. .))
(NP (NP (NN Conclusion)) (: :) (S (NP (NP (DT A) (JJR better) (NN understanding)) (PP (IN of) (SBAR (WHADVP (WRB how)) (S (NP (DT the) (NN drug)) (VP (VBZ works) (PP (IN in) (NP (DT the) (JJ real) (NN world)))))))) (VP (MD can) (VP (VB complement) (NP (NP (JJ clinical) (NNS trials)) (CC and) (NP (NN precision) (NN medicine)))))) (. .))
